Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
A-HYDROCORT vs PROAIR RESPICLICK
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrocortisone is a corticosteroid hormone that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, inhibit immune response, and regulate metabolism.
Selective beta-2 adrenergic receptor agonist; binds to beta-2 receptors on bronchial smooth muscle, activating adenylate cyclase and increasing intracellular cyclic AMP, leading to bronchodilation.
Adrenocortical insufficiency (primary and secondary),Congenital adrenal hyperplasia,Inflammatory conditions (e.g., rheumatoid arthritis, ulcerative colitis),Allergic reactions (severe),Asthma exacerbations,Dermatologic disorders (topical use),Ophthalmic inflammation (ophthalmic use)
Treatment or prevention of bronchospasm in patients aged 4 years and older with reversible obstructive airway disease,Prevention of exercise-induced bronchospasm
Adrenal insufficiency: oral 20-30 mg/day in divided doses; inflammatory conditions: 5-60 mg/day oral; IV/IM: hydrocortisone sodium succinate 50-100 mg every 4-6 hours.
Two inhalations (180 mcg total) orally inhaled every 4 to 6 hours as needed for bronchospasm; for prevention of exercise-induced bronchospasm, 2 inhalations 15 to 30 minutes before exercise.
Terminal half-life: 1.5-2 hours (cortisol); clinical effect persists 8-12 hours due to glucocorticoid receptor binding
Terminal elimination half-life is 3–4 hours for inhaled albuterol; systemic half-life after inhalation is approximately 3.8 hours, supporting q4-6h dosing.
Primarily hepatic via CYP3A4 and other CYP450 enzymes, with reduction in the A-ring to inactive metabolites (e.g., tetrahydrocortisol).
Primarily metabolized by catechol-O-methyltransferase (COMT) and sulfatase enzymes; minor hepatic metabolism via CYP450 enzymes.
Renal (primarily as metabolites, <1% unchanged); biliary/fecal (<5%)
Primarily renal (60–70% as unchanged drug and metabolites, mainly as 4'-O-sulfate ester); biliary/fecal excretion accounts for <20%.
90-95% bound to corticosteroid-binding globulin (CBG) and albumin
Approximately 50–65% bound to plasma proteins (primarily albumin).
0.5-0.8 L/kg; represents distribution into total body water, higher in obesity
1.5–2.5 L/kg (large Vd indicates extensive extravascular distribution, including lung tissue).
Oral: 96% (well absorbed); IM/IV: 100%; topical: minimal systemic absorption (<1% with intact skin)
Inhalation: 10–20% (systemic absorption from lungs and GI tract following swallowed fraction).
No specific adjustment required; monitor fluid/electrolytes in severe renal impairment.
No dosage adjustment required for renal impairment; pharmacokinetics not significantly altered.
Dose reduction may be necessary in severe hepatic impairment; caution as metabolism is hepatic.
No specific dosage adjustment recommended based on Child-Pugh classification; pharmacokinetics not studied in hepatic impairment.
Doses are weight-based; for adrenal insufficiency: 0.5-0.75 mg/kg/day in divided doses; for anti-inflammatory: 0.5-10 mg/kg/day.
Children 4 to 11 years: 2 inhalations (180 mcg total) orally inhaled every 4 to 6 hours as needed; for exercise-induced bronchospasm, 2 inhalations 15 to 30 minutes before exercise.
Use lowest effective dose; monitor for osteoporosis, hypertension, and glucose intolerance.
No specific dosage adjustment required; use caution due to potential for increased sensitivity to sympathomimetic effects; monitor for adverse effects such as tremor, tachycardia, or elevated blood pressure.
None.
None
Immunosuppression and increased infection risk,Adrenal suppression with prolonged use,Cushing's syndrome with chronic use,Osteoporosis with long-term use,GI perforation risk in inflammatory bowel disease,Growth suppression in children,Fetal harm (category C),Ocular effects (cataracts, glaucoma),Fluid and electrolyte disturbances
Paradoxical bronchospasm may occur, which can be life-threatening,Cardiovascular effects: increased heart rate, blood pressure, or ECG changes; use caution in patients with cardiovascular disorders,Fatalities reported with excessive use,Immediate hypersensitivity reactions (urticaria, angioedema, rash),Do not exceed recommended dose; excessive use may lead to death,Hypokalemia and hyperglycemia may occur, especially with high doses
Systemic fungal infections,Hypersensitivity to hydrocortisone or any component,Administration of live or live-attenuated vaccines (relative),Herpes simplex keratitis (topical ophthalmic use),Peptic ulcer disease (relative),Uncontrolled hypertension (relative)
Hypersensitivity to albuterol or any ingredient in the formulation
No specific food interactions. However, high-sodium foods may exacerbate fluid retention; a low-sodium diet is recommended if edema occurs. Grapefruit juice does not significantly affect hydrocortisone. Avoid alcohol due to additive gastric irritation.
No specific food interactions. Avoid xanthine-containing foods (caffeine) if experiencing excessive stimulation; however, no direct interaction with albuterol.
Hydrocortisone is a corticosteroid. Use during first trimester is associated with increased risk of oral clefts (odds ratio 1.5-3.0). Second and third trimester use may cause fetal adrenal suppression, growth restriction, and premature birth. Risk of premature rupture of membranes and intrauterine growth restriction increases with prolonged use.
Pregnancy Category C. In animal studies, albuterol administered subcutaneously at doses 0.5-50 times the maximum recommended human inhalation dose (MRHID) caused cleft palate, delayed ossification, and decreased fetal weight. No adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies risk. First trimester: Risk cannot be ruled out. Second and third trimesters: Risk of maternal tachycardia, hypoglycemia, and hypokalemia; preterm labor inhibition may occur; avoid use during labor due to risk of transient fetal hypoglycemia.
Hydrocortisone is excreted into breast milk in low concentrations. M/P ratio approximately 0.4-1.0. Doses up to 20 mg/day are considered compatible with breastfeeding. Higher doses may suppress infant adrenal function; monitor infant for growth and adrenal suppression.
Albuterol is excreted into human milk in small amounts (M/P ratio not established). Estimated infant dose <1% of maternal weight-adjusted dose. No published adverse effects. Use with caution, especially in preterm infants. Monitor infant for signs of sympathetic stimulation (tachycardia, irritability).
Due to increased clearance and protein binding changes, doses may need to be increased by 50-100% in the second and third trimesters. Monitor clinical response and adjust dose accordingly. Stress doses (e.g., 50-100 mg IV) should be given during labor and delivery.
No specific dose adjustment recommended for pregnant women. However, pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) may theoretically reduce systemic exposure; monitor therapeutic response. Use lowest effective dose to minimize risk of tachycardia and hypokalemia.
For acute adrenal insufficiency, give IV bolus of 100 mg hydrocortisone followed by 100 mg every 8 hours. Taper to oral replacement over days. In septic shock, stress-dose hydrocortisone (200 mg/day) may be used if vasopressor-dependent. Monitor for hyperglycemia, hypokalemia, and immunosuppression. Abrupt discontinuation can cause adrenal crisis.
PROAIR RESPICLICK is a breath-actuated inhaler containing albuterol sulfate, a short-acting beta-2 agonist (SABA). It does not require coordination between actuation and inhalation, making it suitable for patients with difficulty using traditional MDIs. Priming is needed after 7 days of non-use or if dropped; shake well before each use. Monitor for paradoxical bronchospasm and excessive use indicating poorly controlled asthma.
Take exactly as prescribed; do not stop suddenly without doctor's guidance.,Carry a medical alert card or bracelet indicating you take hydrocortisone.,Report signs of adrenal crisis: severe weakness, dizziness, nausea, vomiting, abdominal pain.,During illness or stress (e.g., surgery, infection), dose may need temporary increase; contact your doctor.,Avoid live vaccines during therapy.,Monitor for weight gain, swelling, mood changes, or high blood sugar symptoms (increased thirst, urination).
Use exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Prime the inhaler with 4 test sprays into the air if not used for 7 days or after cleaning or dropping.,Shake the inhaler well before each use.,Breathe out fully, place mouthpiece in mouth, seal lips, and inhale deeply and forcefully to trigger dose delivery.,Hold breath for 10 seconds then exhale slowly.,Rinse mouth with water after each use to prevent oral thrush or throat irritation.,Seek emergency help if symptoms worsen or if relief lasts less than 3 hours.,Store at room temperature away from moisture and heat; do not puncture or incinerate.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about A-HYDROCORT vs PROAIR RESPICLICK, answered by our medical review team.
A-HYDROCORT is a Corticosteroid that works by Hydrocortisone is a corticosteroid hormone that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, inhibit immune response, and regulate metabolism.. PROAIR RESPICLICK is a Beta-2 Agonist Bronchodilator that works by Selective beta-2 adrenergic receptor agonist; binds to beta-2 receptors on bronchial smooth muscle, activating adenylate cyclase and increasing intracellular cyclic AMP, leading to bronchodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between A-HYDROCORT and PROAIR RESPICLICK depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of A-HYDROCORT is: Adrenal insufficiency: oral 20-30 mg/day in divided doses; inflammatory conditions: 5-60 mg/day oral; IV/IM: hydrocortisone sodium succinate 50-100 mg every 4-6 hours.. The standard adult dose of PROAIR RESPICLICK is: Two inhalations (180 mcg total) orally inhaled every 4 to 6 hours as needed for bronchospasm; for prevention of exercise-induced bronchospasm, 2 inhalations 15 to 30 minutes before exercise.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between A-HYDROCORT and PROAIR RESPICLICK in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. A-HYDROCORT is classified as Category C. Hydrocortisone is a corticosteroid. Use during first trimester is associated with increased risk of oral clefts (odds ratio 1.5-3.0). Second and third trimester use may cause fetal. PROAIR RESPICLICK is classified as Category C. Pregnancy Category C. In animal studies, albuterol administered subcutaneously at doses 0.5-50 times the maximum recommended human inhalation dose (MRHID) caused cleft palate, dela. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.